Archives — March 2017 back to current month (6)
With a swab taken from the inside of a patient's cheek, 3D Signatures' TeloView platform has demonstrated its ability to diagnose Alzheimer's disease, and also to assess whether the disease is manifesting in a mild, moderate or severe form.
Therapix Biosciences launches its IPO on NASDAQ on Wednesday, March 22, under the trading symbol TRPX. The Tel Aviv-based company specializing in the development and commercialization of cannabinoid-based treatments has a drug for Tourette Syndrome in Phase 2a trials and is additionally developing a drug for mild cognitive impairment. The IPO helps put it on a path to join much larger companies developing cannabinoid-based drugs.
RepliCel's successful conclusion of its Phase 1 trial for hair loss sets it up for the next steps in the drug's development.
3D Signatures continues to advance its cutting-edge technology for prostate cancer liquid biopsies and Hodgkin's lymphoma tests.
Stellar Biotechnologies and Amaran Biotechnology have entered into an exclusive agreement where Stellar will supply KLH to the biopharmaceuticals manufacturer.
Several KLH-based vaccines are in trials for indications as varied as breast cancer and lupus, and clinical success could propel Stellar Biotechnologies, which is the only provider of KLH that has its own aquaculture facilities, says Jason McCarthy, an equity research analyst with Maxim Securities. Maxim currently has a price target of $4 on Stellar and the stock currently trades at around $1.65.
|"Based on RXI's new checkpoint inhibitors and the potential for multiple partnering deals, we are maintaining our Buy recommendation."|
|"We initiate with an Outperform on VIVE."|
|"RVX remains gravely undervalued at the current share price."|
|"RGS' strategy is to partner its product opportunities for development and commercialisation, allowing it to focus on early-stage product development."|
|"We continue to be optimistic about DRRX's story."|